Patents by Inventor Cyrille Lescop

Cyrille Lescop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 11834443
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: December 5, 2023
    Assignee: Idorsia Pharmaceuticals Ltd
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20230002365
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: July 1, 2022
    Publication date: January 5, 2023
    Inventors: Cyrille LESCOP, Jasper DINGEMANSE, Andreas KRAUSE
  • COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
    Publication number: 20230000846
    Abstract: The present invention concerns the compounds of formula (I) wherein R1, R2, R3, X, and Y are as described in the description, and their use as antagonists of the LPA1 receptor, in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s); such as especially pirfenidone and/or nintedanib, in the prevention and/or treatment of fibrotic diseases. The invention further relates to pharmaceutical compositions comprising the compounds of formula (I) in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s) such as pirfenidone or nintedanib.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 5, 2023
    Inventors: Magdalena BIRKER, Cyrille LESCOP
  • PYRIDIN-3-YL DERIVATIVES
    Publication number: 20220251068
    Abstract: The present invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Ar1, L, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.
    Type: Application
    Filed: June 17, 2020
    Publication date: August 11, 2022
    Inventors: Martin BOLLI, Christine BROTSCHI, Cyrille LESCOP
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
    Patent number: 11390615
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS
    Publication number: 20210246116
    Abstract: The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 12, 2021
    Inventors: Martin BOLLI, Christine BROTSCHI, Cyrille LESCOP, Jodi T. WILLIAMS
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20210024513
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: October 14, 2020
    Publication date: January 28, 2021
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille LESCOP, Jasper DINGEMANSE, Andreas KRAUSE
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 10836754
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 17, 2020
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20190322657
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventor: Cyrille LESCOP
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
    Patent number: 10385043
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: August 20, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventor: Cyrille Lescop
  • CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL
    Publication number: 20180141936
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Application
    Filed: May 19, 2016
    Publication date: May 24, 2018
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventor: Cyrille LESCOP
  • Pyridin-4-yl derivatives
    Patent number: 9617250
    Abstract: The invention relates to compounds of the Formula (I), Formula (I) wherein R1 and R2 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 11, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Cyrille Lescop, Oliver Nayler, Beat Steiner
  • PYRIDIN-4-YL DERIVATIVES
    Publication number: 20160031866
    Abstract: The invention relates to compounds of the Formula (I), Formula (I) wherein R1 and R2 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Cyrille Lescop, Oliver Nayler, Beat Steiner
  • 2-methoxy-pyridin-4-yl-derivatives
    Patent number: 9133179
    Abstract: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 15, 2015
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
  • Pyridin-4-yl derivatives
    Patent number: 8658675
    Abstract: The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: February 25, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
  • Pyridine derivatives as S1P1/EDG1 receptor modulators
    Patent number: 8598208
    Abstract: The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: December 3, 2013
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner, Jorg Velker
  • 2-METHOXY-PYRIDIN-4-YL-DERIVATIVES
    Publication number: 20130303514
    Abstract: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Application
    Filed: January 18, 2012
    Publication date: November 14, 2013
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
  • Pyridin-2-yl derivatives as immunomodulating agents
    Patent number: 8575200
    Abstract: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: November 5, 2013
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner
  • Aminomethyl benzene derivatives
    Patent number: 8410151
    Abstract: The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: April 2, 2013
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner
  • Pyrimidine derivatives
    Patent number: 8299086
    Abstract: The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: October 30, 2012
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner